Wave Life Sciences Announces Nature Biotechnology Publication Highlighting First RNA Base Editing in Non-Human Primates Using an Endogenous Enzyme
March 07, 2022 11:14 ET
|
Wave Life Sciences USA, Inc.
Published data demonstrate potent, durable, and specific editing and potential for therapeutic applications in liver using a subcutaneous GalNAc-conjugated oligonucleotide approach Wave’s...
Wave Life Sciences Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update
March 03, 2022 07:30 ET
|
Wave Life Sciences USA, Inc.
Clinical data from multiple novel, PN-modified stereopure oligonucleotides for ALS/FTD, DMD, and HD expected in 2022 GalNAc-AIMers restore therapeutically relevant levels of AAT for lung...
Wave Life Sciences to Webcast Conference Call of Fourth Quarter and Full Year 2021 Financial Results on March 3, 2022
February 24, 2022 08:30 ET
|
Wave Life Sciences USA, Inc.
CAMBRIDGE, Mass., Feb. 24, 2022 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people...
Wave Life Sciences to Present at the Virtual 11th Annual SVB Leerink Global Healthcare Conference 2022
February 09, 2022 08:30 ET
|
Wave Life Sciences USA, Inc.
CAMBRIDGE, Mass., Feb. 09, 2022 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people...
Wave Life Sciences Announces Two Papers in the Journal Nucleic Acids Research Describing How PN Backbone Chemistry Modifications Enhance the Pharmacological Effects of Oligonucleotides
February 02, 2022 16:05 ET
|
Wave Life Sciences USA, Inc.
Wave paper on PN chemistry for silencing in the CNS, and the implications for oligonucleotides more broadly, designated as a Breakthrough Article by Nucleic Acids Research Publications highlight the...
Wave Life Sciences Reports Third Quarter 2021 Financial Results and Provides Business Update
November 10, 2021 07:30 ET
|
Wave Life Sciences USA, Inc.
Strengthened balance sheet with approximately $52 million; focusing additional investment in RNA editing programs led by hepatic editing Optimized AIMers for AATD program demonstrate potent, highly...
Wave Life Sciences to Present at the Stifel 2021 Virtual Healthcare Conference
November 08, 2021 16:05 ET
|
Wave Life Sciences USA, Inc.
CAMBRIDGE, Mass., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people...
Wave Life Sciences to Webcast Conference Call of Third Quarter 2021 Financial Results on November 10, 2021
November 01, 2021 08:30 ET
|
Wave Life Sciences USA, Inc.
CAMBRIDGE, Mass., Nov. 01, 2021 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people...
Wave Life Sciences and Takeda Amend CNS Collaboration
October 18, 2021 17:00 ET
|
Wave Life Sciences USA, Inc.
Amendment to ongoing collaboration allows Wave to advance or partner CNS programs, including those using ADAR editing Takeda option to co-develop and co-commercialize late-stage CNS programs,...
Wave Life Sciences Announces Initiation of Dosing in Phase 1b/2a Clinical Trial of WVE-N531 in Duchenne Muscular Dystrophy
September 29, 2021 08:30 ET
|
Wave Life Sciences USA, Inc.
Trial is expected to enroll 15 boys with DMD amenable to exon 53 skipping First systemically administered therapeutic candidate with PN backbone chemistry modifications to be assessed in the clinic ...